Related Experiment Video

Updated: Jun 20, 2025

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.3K

Comparison of Drug Therapy Efficacy in Patients With Hypertrophic Cardiomyopathy: A Network Meta-Analysis

Erhan Shang1, Hongmei Tan1

  • 1School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Shenzhen, Guangdong, China.

The American Journal of Cardiology
|July 17, 2024
PubMed

Insights

This network meta-analysis compared hypertrophic cardiomyopathy (HCM) drugs. Mavacamten and perhexiline improved exercise capacity, while mavacamten also reduced key cardiac markers.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Hypertrophic cardiomyopathy (HCM) is a complex genetic heart condition.
  • Effective pharmacological treatments for HCM are crucial for improving patient outcomes.
  • Existing treatments vary in efficacy and impact on disease markers.

Purpose of the Study:

  • To conduct a network meta-analysis comparing the efficacy of commonly used drugs for treating hypertrophic cardiomyopathy (HCM).
  • To evaluate the impact of various pharmacological agents on key clinical and biomarker outcomes in HCM patients.

Main Methods:

  • Systematic search of major databases (PubMed, Embase, Cochrane, Web of Science) for randomized controlled trials up to January 10, 2024.
  • Inclusion of 17 studies involving 1,133 patients with HCM.
  • Quality assessment using risk of bias tool and data analysis with R software.

Main Results:

  • Mavacamten and perhexiline significantly improved peak oxygen consumption compared to placebo.
  • Mavacamten demonstrated reductions in N-terminal pro-B-type natriuretic peptide, left ventricular mass index, left atrial volume index, and septal E/e' ratio.
  • Candesartan, mavacamten, and valsartan reduced maximum wall thickness; perhexiline showed superior efficacy in increasing peak oxygen consumption.

Conclusions:

  • Commonly used drugs offer benefits for specific outcome measures in HCM treatment.
  • The novel drug mavacamten shows significant therapeutic effects across multiple measures, excluding left ventricular ejection fraction.
  • Further research may elucidate optimal drug combinations and long-term efficacy in managing HCM.

Keywords:
HCMNMAcommonly used drugsmavacamtenoutcome measures

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.0K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
418
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
155
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
563
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.3K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
361